What Is a Free PSA Test, How Is It Done, and What Should the Ideal Value Be?
In this article
What Is a Free PSA Test? And How Has the Path After PSA Changed?
How free PSA works has not changed. What has changed is what happens after an elevated PSA. Ten years ago, the sequence was: elevated PSA → biopsy → treatment if cancer is found. Today, both links in this chain have broken: between PSA and biopsy came MRI and between diagnosis and treatment came active surveillance. These two changes have completely transformed what "my PSA is high" means.
- High PSA no longer directly means biopsy. In a study using MRI before biopsy, among men, %28 avoided biopsy entirely; nevertheless, more significant cancers (%38 versus %26), and fewer insignificant cancers (%9 versus %22) were detected.
- Even a diagnosis does not require a rushed decision. In the ProtecT study's 15-year results, prostate cancer mortality in active surveillance, surgery and radiotherapy arms was, respectively, %3,1, %2,2 and %2,9 — with no significant difference. During the same period, %21,7 died from other causes.
- The free PSA ratio is now lower in the hierarchy. The order is: MRI > PHI and 4Kscore > free/total PSA ratio. The European guideline gives MRI a strongrecommendation, and blood markers a weak recommendation.
- Old Preparation Warnings Are Outdated. In the current guideline's words, neither digital examination nor cycling appreciably alters PSA; ejaculation either has no effect or an effect of around %10. The "48 hours of sexual abstinence" rule no longer applies.
- By contrast, one thing truly matters: finasteride and dutasteride (for prostate enlargement and hair loss) reduce PSA by approximately half — the result must be multiplied by two for interpretation.
- Age-Based "Normal PSA" Tables Are Not Current. PSA has no true normal cutoff; it is a continuous risk indicator.
PSA (prostate-specific antigen)is a protein produced mainly in prostate tissue. In blood it is either bound to other proteins or free.
- Total PSA: measures the sum of both.
- Free PSA: measures only the unbound fraction.
- Free/total ratio: one divided by the other. As the ratio falls, cancer probability risesbecause PSA released from cancerous tissue is more often protein-bound.
Why Are Both Requested Rather Than Just the Ratio? Free PSA alone is not informative; dividing it by total PSA provides information.
Free PSA Ratio: Numbers and Limitations
The study establishing free PSA ratio (1998) was conducted in a very narrow patient group and most Turkish texts omit this limitation:
- Only total PSA between 4-10 ng/mL (the "gray zone")
- Only normal digital rectal examination
- Age 50-75
Outside these limits — for example, PSA of 15 or examination showing firmness — free PSA ratio has no validated value.
| Free/total PSA ratio | Age 50-64 | Age 65-75 |
|---|---|---|
| %0-10 | %56 | %55 |
| Above %25 | %5-9 | %8-9 |
Below %10, biopsy cancer probability exceeds half; above %25, it falls below one in ten. In the study, using the %25 threshold detected %95 of cancers and avoided %20 of biopsies.
The table above is often reproduced with age columns removed although the original study stratified risk by age, and in intermediate bands, older men had higher risk at every level. The same ratio means something different for a man aged 55 and one aged 72.
But This Is No Longer the Main Question: MRI First
The old approach was: high PSA → blind (systematic) biopsy. It had two problems: it missed significant cancerswhile finding insignificant cancers not requiring treatment.
The PRECISION study (n=500) directly tested this. One group went directly to biopsy; the other first had multiparametric prostate MRI and targeted biopsy only for suspicious imaging (PI-RADS 3 or above):
- In the MRI group, %28 of men (71/252) had no biopsy because MRI was clear.
- Clinically significant cancer detection: %38 versus %26 — the MRI group found more significant cancers.
- Insignificant cancer detection: %9 versus %22 — the MRI group found fewer unnecessary diagnoses.
Thus MRI first meant both fewer biopsies and better diagnosis — a rare combination in medicine.
The PROMIS study points the same way: sensitivity for significant cancer was %93 with MRI, %48 with conventional biopsy.
| MRI finding (PI-RADS) | Significant cancer rate on biopsy |
|---|---|
| PI-RADS 5 | %83 |
| PI-RADS 4 | %60 |
| PI-RADS 3 (uncertain) | %12 |
| PI-RADS 1-2 | No biopsy performed |
European Association of Urology: In men with PSA 3-20 ng/mL, MRI before biopsy has a "strong" recommendation level. Blood markers (including PHI, 4Kscore and free PSA ratio) have only a "weak" recommendation level.
American Urological Associations (2026): Prebiopsy MRI is a conditional recommendation, evidence level A. For screening, ages 50-69: PSA every 2-4 years (strong recommendation, level A); initial PSA at 45-50, or 40-45 in high-risk men.
Practical Implication: "My PSA is high; I need an immediate biopsy" is no longer automatically correct. The right question is: "Has an MRI been done?"
According to the guideline, a PI-RADS 3-or-above threshold avoids approximately %30 of biopsiesbut this approach misses %11 of significant cancers. A clear MRI does not mean "definitely no cancer": it substantially reduces risk without eliminating it. PSA monitoring therefore continues afterward.
Even After Diagnosis, No Rushed Decision Is Needed
Men with PSA-screen-detected, prostate-confined cancer were divided into three groups: active surveillance (close monitoring without treatment), surgery and radiotherapy. After 15 years:
| Active surveillance | Surgery | Radiotherapy | |
|---|---|---|---|
| Prostate cancer mortality | %3,1 | %2,2 | %2,9 |
| Metastasis development | %9,4 | %4,7 | %5,0 |
Mortality did not differ significantly between the three groups. During the same period, among men, %21,7 died of other causes — about seven times the prostate cancer deaths. In the active surveillance group, %24,4 received no treatment for 15 years.
But the Table's Second Row Must Also Be Read Honestly: in the active surveillance group, metastasis was approximately twice as frequent (%9,4 versus %4,7-5,0). Surveillance did not increase mortality but increased the likelihood of spread — a real trade-off to discuss with patients.
Another Limitation: ProtecT's surveillance protocol predates MRI and was less strict than current protocols. Surveillance using MRI and targeted biopsy is expected to do better today, but equivalent long-term evidence does not yet exist.
For low-risk prostate cancer, active surveillance is now the preferred approach. In a large registry study (84.596 patients), active surveillance in low-risk patients rose from 2014's %29,6 to 2019's %49,5 as an increase.
But its most striking finding was different: practice variation among physicians ranged from %0 to %100. Thus whether surveillance was recommended could depend less on disease than on which doctor the patient saw as a factor. This is one of the rare situations where a second opinion is truly meaningful.
The Screening Debate: Two Studies, Two Results, One Explanation
| ERSPC (Europe) | PLCO (USA) | |
|---|---|---|
| Result | In prostate cancer mortality, %20 reduction (RR 0,80; %95 CI 0,72-0,89) | No difference (RR 1,04; 0,87-1,24) |
| Patient count | 182.160 | — |
| Critical detail | At 16 years, number needing invitation to save one life: 570; cancers needing detection: 18. These numbers, with longer follow-up, improve (at year 13, they were 742 and 26, respectively). | %86 of control-group men had already had PSA testing. |
Because %86 of PLCO control-group men already had PSA tests, the study effectively compared "regular screening versus opportunistic screening" rather than "screening versus no screening". Its authors describe it this way too.
The shared message is therefore: PSA screening reduces prostate cancer deaths at the cost of many unnecessary diagnoses and treatments. As MRI-first approaches and surveillance become more common, this cost is decreasing — today's benefit–harm balance is better than in 2009.
US Preventive Services Task Force (2018): Screening in men aged 55-69 through shared decision-making (grade C recommendation); age 70 and older: not recommended (grade D). Important: this statement is reportedly being updated.
Council of the European Union (9 December 2022): Cancer screening recommendations now include prostate cancer with this proposed approach: "PSA testing... combined with additional MRI scanning as follow-up" for gradual evaluation of organized programs. No specific age range is provided.
Europe is therefore moving from "do not screen" toward "organized, risk-adapted screening with MRI" as the direction.
Where Does Free PSA Stand in Today's Hierarchy?
| Rank | Method | Guideline position |
|---|---|---|
| 1 | Multiparametric MRI | Before biopsy for PSA 3-20 strong recommendation |
| 2 | PHI (Prostate Health Index) and 4Kscore | Compared with free/total PSA ratio, they perform better as reported. Discrimination for PHI: 0,74; for free PSA ratio: 0,63 (8 studies, 2.969 men). |
| 3 | Free/total PSA ratio | Still usable but only with a weak recommendation and valid in a narrow patient group |
This Does Not Mean Free PSA Is Useless — it may still reduce unnecessary biopsies where MRI access is limited. But "let's measure free PSA and decide" is outdated when MRI is available.
Factors Affecting PSA: Most Old Warnings Are Outdated
Finasteride and dutasteride (for prostate enlargement and, at lower doses, hair loss) lower PSA by approximately half within about six months.
Practical Rule: In a man taking these drugs, PSA should be multiplied by two for interpretation. A measured 2,5 ng/mL is therefore interpreted like 5 ng/mL.
An Even More Important Rule: In men taking these drugs, any confirmed rise from the lowest value (nadir)because PSA is already suppressed by medication, must be taken seriously.
Often Overlooked: Patients often do not consider low-dose finasteride for hair loss a "medicine" and do not tell their physician. Always mention hair-loss medication before PSA testing. Without this information, a clinically meaningful elevation may appear "normal".
The current guideline states verbatim: "Neither digital rectal examination nor cycling appreciably alters PSA; most controlled studies evaluating ejaculation show either no significant effect or a slight increase of approximately %10."
Thus the long-repeated warnings, "48 hours of sexual abstinence before testing", "do not cycle", "draw blood before examination" are unsupported by current evidence.
What Truly Matters: Urinary infection or prostatitis substantially increases PSA; testing should therefore be postponed until infection is treated. Some waiting is also needed after prostate procedures (biopsy, catheterization, surgery).
The table widespread in Turkish sources (under 49: 2,5; 50-59: 3,5; 60-69: 4,5; over 70: 6,5) comes from a study in 1993 and is adopted by no current guideline.
Today's understanding is: PSA has no true "normal cutoff". It is a continuous risk indicator: higher values mean higher risk, without a line separating "disease" from "health". A value of 3 ng/mL means something different at age 50 than at 75. Decisions depend not only on the number but on PSA trends over time, prostate volume, examination, family history and life expectancy as factors.
Frequently Asked Questions
My Free PSA Ratio Is Low. Do I Have Cancer?
No. A low ratio adjusts probability; it is not a diagnosis. In Catalona's 1998 data, around half of men in the %0-10 range had cancer on biopsy, meaning half did not. Today's correct next step is multiparametric prostate MRI rather than direct biopsy. Some men with clear MRI can avoid biopsy.
My Free PSA Ratio Is High. Is Follow-Up Unnecessary?
Follow-up is needed. Above %25, biopsy cancer probability is around %5-9, not zero. Also, the ratio was studied only with total PSA 4-10 ng/mL and benign digital rectal examination. Outside this range, its meaning is uncertain.
Must I Avoid Sex, Cycling or Digital Examination Before Blood Testing?
Current guidelines do not support these warnings. AUA/SUO 2026 states such restrictions are not routinely recommended before PSA testing. Clinically meaningful, reproducible elevations cannot be explained by these transient factors. Active urinary infection or recent prostate procedures, however, cause real, large elevations; testing should then be postponed.
I Take Finasteride for Hair Loss. How Is PSA Interpreted?
5-alpha reductase inhibitors (finasteride, dutasteride) lower PSA by about half. After more than six months, doubling the measured value is common practice. More importantly, any confirmed rise from the on-treatment nadir requires investigation even if still "normal". Unless you mention low-dose hair-loss use, the result may be misread.
PSA Is High but MRI Is Clear. Will I Avoid Biopsy?
Decide with your physician. In PRECISION's MRI-based arm, %28 avoided biopsy. But MRI can miss cancers: using PI-RADS 3 or above may miss around %11 of clinically significant cases. "Clear MRI" usually means "postpone biopsy and tighten PSA follow-up", not "case closed".
If Cancer Is Found, Will I Need Immediate Surgery?
No. In ProtecT's 15-year results, %24,4 assigned to surveillance received no radical treatment for fifteen years. Prostate cancer mortality across three arms remained close at %3,1, %2,2 and %2,9. In low-risk disease, surveillance is a guideline-recommended standard option, not "refusing treatment".
Is There a Better Test Than Free PSA?
The hierarchy is multiparametric MRI at the top, second-generation blood tests such as PHI and 4Kscore in the middle, and free PSA ratio at the bottom. PHI's pooled AUC is 0,74 versus around 0,63 for free PSA. Free PSA's advantage is low cost and availability, not superiority.
Glossary
Total PSA: All blood-measured prostate-specific antigen: free and protein-bound fractions combined.
Free PSA: PSA circulating unbound to proteins, used as a ratio to total PSA rather than alone.
Free PSA ratio (%fPSA): Free PSA divided by total PSA and multiplied by one hundred. A low ratio increases cancer probability; a high ratio suggests benign enlargement.
Clinically significant prostate cancer (csPCa): Cancer potentially harmful if untreated. PROMIS defined it as disease containing primary Gleason 4 or a maximum cancer core length of at least 6 mm.
Multiparametric MRI (mpMRI): Prostate MRI using multiple sequences (T2, diffusion, dynamic contrast).
PI-RADS: A reporting system grading prostate MRI findings from 1 to 5 by likelihood of significant cancer.
Fusion biopsy: Overlaying MRI and ultrasound images to target sampling from a suspicious focus.
Active surveillance: Close PSA, MRI and repeat-biopsy monitoring for low-risk cancer instead of immediate treatment; treatment begins with signs of progression.
Overdiagnosis: Finding a cancer that would never cause symptoms or harm during the person's life.
Lead-time bias: Apparently longer survival because disease is detected earlier, although the time of death is unchanged.
NNI / NND: Number needing screening to detect one cancer (NNI), and cancers needing detection to save one life (NND).
5-ARI: 5-alpha reductase inhibitors: finasteride and dutasteride. Approximately halve PSA.
DROZDOGAN Academy Commentary
Most Turkish texts attach correct free PSA physiology to a decade-old decision pathway. The physiology remains correct; the chain is broken.
⚡ Why It Matters: The old model had three links: elevated PSA, biopsy, treatment if cancer is found. Both connections have now broken. Multiparametric MRI sits between PSA and biopsy, and surveillance between diagnosis and treatment. Presenting free PSA ratio as the answer to "should I have a biopsy?" sends patients along an outdated road map.
✅ Strengths: The ratio's biological basis is sound and measurement cheap, widespread and reproducible. Catalona's 1998 data show a real, large probability difference between %0-10 and above %25. It can still reduce unnecessary biopsies where MRI access is limited. ProtecT's 15-year data offer separate reassurance: delaying early-disease treatment had no measurable mortality cost over the study period.
⚠️ Limitations: Its limits are often omitted: validated only for total PSA 4-10 ng/mL, benign rectal examination and men aged 50-75. Many Turkish sources remove age columns, obscuring different meanings at ages 55 and 75. Discrimination is modest: PHI AUC 0,74 versus free PSA around 0,63. ProtecT's limitation also matters: patients were diagnosed with systematic biopsy before the MRI era; today's pathway is more selective.
🩺 What to Do in Practice:
- Interpret free PSA with total PSA range, age and digital rectal findings, not alone.
- Ask whether multiparametric prostate MRI is appropriate before biopsy for elevated PSA.
- Always mention 5-alpha reductase inhibitor use, even low hair-loss doses.
- Know that pretest abstinence and cycling restrictions are not in current guidelines, but postpone testing during active urinary infection.
- If cancer is diagnosed, before asking "what do we do immediately?", ask "is this suitable for surveillance?".
❓ Open Questions: Reliable, current national data on stage at diagnosis and prostate MRI access in Türkiye are unavailable. MRI-based pathways' long-term mortality effects have not been demonstrated in randomized data: PRECISION and PROMIS assess diagnostic accuracy, not survival. Optimal MRI and biopsy intervals during surveillance remain debated.
Our Brief Verdict: Free PSA remains a usable aid, but no longer a decision point. In 2026, the right question is not "what is my free PSA ratio?" but "after elevated PSA, should I have MRI, a second-generation blood test or direct follow-up?" Even diagnosis no longer equates "cancer exists" with "immediate treatment is needed".
Transparency Note
The following points could not be verified or were deliberately omitted:
- Stage distribution at diagnosis in Türkiye and access to prostate MRI and fusion biopsy lacked current, verifiable national sources, so no figures were given.
- SGK / SUT reimbursement status was not stated for any test or imaging. These details change often and may mislead patients if unverified; confirm current status with the hospital medical board unit.
- The NCCN guideline was accessible only in an older version (v2.2019); it was therefore not cited by version, and current recommendations came from EAU and AUA/SUO.
- Türkiye Epidemiology Data differ between two sources: Ministry of Health 2020 statistics give age-standardized incidence 38,0/100.000 and 6.106 new cases; the Global Cancer Observatory Türkiye page labeled 2024 gives 18.749 cases, 4.851 deaths, standardized incidence 33,5 and mortality 13,8. The sources were not averaged; pay attention to the data year.
- Technical restrictions prevented access to some large studies' primary texts, so numerical data were verified from detailed, authoritative secondary sources. Catalona 1998, the EAU guideline, AUA/SUO 2026, the Council of Europe recommendation, finasteride product information and the Turkish Ministry of Health report were read directly.
- Nothing in this article replaces personal medical advice. PSA interpretation depends on age, prostate volume, examination, family history and medications.
References
- Kasivisvanathan V, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis (PRECISION). N Engl J Med. 2018;378(19):1767-1777.
- Ahmed HU, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822.
- Hamdy FC, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT). N Engl J Med. 2023;388(17):1547-1558.
- Catalona WJ, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998;279(19):1542-1547.
- Hugosson J, Roobol MJ, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2019;76(1):43-51.
- Andriole GL, et al. Prostate Cancer Screening in the Randomized PLCO Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
- US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901-1913.
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology.
- Early Detection of Prostate Cancer: AUA/SUO Guideline. American Urological Association / Society of Urologic Oncology, 2026.
- Council Recommendation on strengthening prevention through early detection: A new EU approach on cancer screening. Council of the European Union, 9 December 2022.
- Cooperberg MR, et al. Active surveillance patterns in the AUA Quality (AQUA) Registry.
- Prostate Health Index (PHI) diagnostic accuracy meta-analysis, pooled AUC data.
- Finasteride and dutasteride product information (PSA interpretation section).
- Republic of Türkiye Ministry of Health, General Directorate of Public Health. Türkiye Cancer Statistics 2020.
- Global Cancer Observatory (IARC), Türkiye country page, dataset labeled 2024.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.